drugset / Trial / NCT05954897
Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of lenvatinib, tislelizumab combined with RALOX regimen HAIC in advanced hepatocellular carcinoma.
Timeline
- Start
- 2023-09-01
- Primary completion
- 2026-01-01
- Completion
- 2027-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | — | — |
| Subject | Tislelizumab | Monoclonal antibody | — | — |